• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Subcutaneous casirivimab and imdevimab reduced symptomatic COVID-19 infection among asymptomatic positive individuals

byJake EngelandMichael Pratte
January 20, 2022
in Emergency, Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Close household contacts of SARS-CoV-2-infected individuals, who were asymptomatic and positive on RT-qPCR, had a significantly reduced risk of progression to symptomatic infection if treated with subcutaneous casirivimab and imdevimab compared to placebo.

2. The length of high viral load and duration of symptoms among those who became symptomatic were significantly reduced among casirivimab and imdevimab-treated participants.

Evidence Rating Level: 1 (Excellent)

Study Rundown: There is high demand during the COVID-19 pandemic to discover ways of slowing the spread and reducing infection rates. Casirivimab and imdevimab are monoclonal antibodies that bind the SARS-CoV-2 spike protein and prevent the entry of the virus into the body. This phase 3 randomized clinical trial investigated whether subcutaneous casirivimab and imdevimab can reduce progression to symptomatic SARS-CoV-2 infection among baseline asymptomatic close household contacts of infected individuals. This trial was conducted between July 13, 2020, and January 28, 2021, at 112 United States sites. Participants were randomized to receive one dose of casirivimab and imdevimab (n= 158) or placebo (n= 156) within 96 hours of the infected individual’s positive SARS-CoV-2 test. The primary outcome was the proportion of close contact participants who had a positive RT-qPCR result at baseline or within 28 days and developed signs and symptoms of COVID-19 within 14 days of the positive test result. Subcutaneous casirivimab and imdevimab significantly reduced the risk of symptomatic infection within 14 days of a positive RT-qPCR test compared to placebo (29/100 [29.0%] vs. 44/104 [42.3%]; odds ratio [OR]: 0.54 [95% CI: 0.30-0.97]; p= 0.04). Among symptomatic participants, the duration of symptoms was reduced by an average of 5.6 days in the treatment group compared to placebo (21.7 days vs 27.3 days; p= 0.03). Furthermore, the number of weeks with a high viral load (defined as >4 log10 copies/mL) in nasopharyngeal swab samples was significantly reduced among treated patients (489.6 weeks vs. 811.9 weeks per 1000 participants; p= 0.001). Overall, subcutaneous treatment with casirivimab and imdevimab demonstrated significantly reduced progression to symptomatic SARS-CoV-2 infection among asymptomatic, infected, close household contacts. Notably, this trial was conducted before widespread vaccination and onset of variants, such as Delta and Omicron; therefore, further studies are required to elucidate whether these results are consistent during different phases of the pandemic.

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

Relevant Reading: Subcutaneous REGEN-COV antibody combination to prevent COVID-19

RELATED REPORTS

Awake prone positioning does not seem to offer benefit in reducing endotracheal intubation for COVID-19-induced acute respiratory failure: COVI-PRONE trial

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: COVID-19
Previous Post

#VisualAbstract: Adolescents had an increased risk of all-cause mortality over younger children with Hodgkin lymphoma

Next Post

Coronary artery bypass grafting reduces rate of myocardial infarctions compared to percutaneous coronary intervention for left main coronary artery disease

RelatedReports

Novel coronavirus identified from patients with pneumonia in Wuhan, China
Emergency

Awake prone positioning does not seem to offer benefit in reducing endotracheal intubation for COVID-19-induced acute respiratory failure: COVI-PRONE trial

May 16, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Vaccination boosted immunity acquired from previous SARS-CoV-2 infection

May 13, 2022
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Chronic Disease

Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes

May 13, 2022
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

BNT162b2 safe and efficacious in children 5 to 11 years of age

May 13, 2022
Next Post
Cognitive outcomes in older adults undergoing cardiovascular procedures unclear

Coronary artery bypass grafting reduces rate of myocardial infarctions compared to percutaneous coronary intervention for left main coronary artery disease

Increasing C-section room temperature linked to reduced neonatal, maternal hypothermia

Trends in morbidity and mortality of extremely preterm infants in the United States

Intentional injuries leading to ED visits often occur at school

COVID-19 instructional approaches differentially impacted sleep patterns among students

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.